Faroe Islands vs New Zealand: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Faroe Islands
0.0%
in 2024
New Zealand
0.0%
in 2024
Faroe Islands rank
167th
New Zealand rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Faroe Islands
- New Zealand
How they compare
Faroe Islands currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
Across all 10 years both countries report, New Zealand has been ahead every year.
Faroe Islands ranks 167th and New Zealand ranks 167th of 246 countries.
Head to head by decade
| Decade | Faroe Islands | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Faroe Islands or New Zealand?
- Faroe Islands, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Faroe Islands and New Zealand?
- 0.0%, with Faroe Islands ahead.
- How many years of comparable data are there for Faroe Islands and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do Faroe Islands and New Zealand rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Faroe Islands ranks 167th and New Zealand ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.